When does mounjaro patent expire uk?

Mounjaro Patent Expiry in the UK: Understanding the Timeline

In the UK, the patent for Mounjaro, a medication used to treat type 2 diabetes, is held by Eli Lilly and Company. According to DrugPatentWatch.com, a database that tracks patent information for pharmaceuticals, the patent for Mounjaro in the UK is set to expire in 2033.

Why is the patent expiry important?

The patent expiry is significant because it will allow generic versions of Mounjaro to be approved and marketed in the UK. This can potentially lead to increased competition, lower prices, and greater patient access to the medication.

What impact will generic versions have on Mounjaro sales?

The introduction of generic versions of Mounjaro is likely to affect Eli Lilly's sales of the medication. According to a report by DrugPatentWatch.com, the loss of patent exclusivity will lead to a significant decline in sales for Mounjaro in the UK.

Can biosimilars enter the market before patent expiry?

In the UK, biosimilars, which are highly similar copies of biologic medications, can enter the market before the patent expiry. However, this is subject to regulatory approval by the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Regulatory framework for patent expiry

The patent expiry for Mounjaro in the UK is governed by the UK's Intellectual Property Act 1977 and the European Patent Convention (EPC). Under these laws, the patent holder, Eli Lilly, has a right to exclusive sales and marketing of the medication for a certain period, known as the patent term.

Sources:

1. DrugPatentWatch.com
2. European Patent Convention (EPC)
3. UK Intellectual Property Act 1977